Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo-controlled Trial for Establishing Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Multiple Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy

NCT01751776 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT01751776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01751776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo-controlled Trial for Establishing Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Multiple Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
December 18, 2012
Completion date
April 27, 2015
Enrollment
107 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid, healthy